ABT-431, a selective D1 agonist has efficacy in patients with Parkinson's disease

被引：0
|
作者：
Rascol, O
Blin, O
Descombes, S
Soubrouilliard, C
Fabre, N
Viallet, F
Thalamas, C
Azulay, JP
Lafnitzegger, K
Fredrick, E
Wright, S
Nutt, J
机构：
来源：
NEUROLOGY | 1997年 / 48卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：32004 / 32004
页数：2
相关论文
共 50 条
  • [21] Dinapsoline:: Characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease
    Gulwadi, AG
    Korpinen, CD
    Mailman, RB
    Nichols, DE
    Sit, SY
    Taber, MT
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2001, 296 (02): : 338 - 344
  • [22] SETTING THE TEMPO: A PHASE 3 PROGRAM TO INVESTIGATE TAVAPADON, A SELECTIVE D1/D5 PARTIAL AGONIST, FOR PARKINSON'S DISEASE
    Fernandez, H. F.
    Pfister, S. P.
    Leoni, M.
    Berry, M.
    Gangadharan, A.
    Duvvuri, S.
    Parker, J.
    Wang, S.
    Briscoe, R. B.
    Sanchez, R.
    [J]. PARKINSONISM & RELATED DISORDERS, 2023, 113 : 48 - 48
  • [23] Hyperactivity and behavioral seizures in rodents following treatment with the dopamine D-1 receptor agonists A-86929 and ABT-431
    Shiosaki, K
    Asin, KE
    Britton, DR
    Giardina, WJ
    Bednarz, L
    Mahan, L
    Mikusa, J
    Nikkel, A
    Wismer, C
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 317 (2-3) : 183 - 190
  • [24] The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease
    Schrag, AE
    Brooks, DJ
    Brunt, E
    Fuell, D
    Korczyn, A
    Poewe, W
    Quinn, NP
    Rascol, O
    Stocchi, F
    [J]. CLINICAL NEUROPHARMACOLOGY, 1998, 21 (03) : 169 - 175
  • [25] Central dopaminergic D1 agonists in the treatment of Parkinson's disease
    Soubrouillard, C
    Lombardo, C
    Rascol, O
    Bruguerolle, B
    Blin, O
    [J]. THERAPIE, 1997, 52 (06): : 527 - 534
  • [26] Evaluation of D1/D5 Partial Agonist PF-06412562 in Parkinson's Disease following Oral Administration
    Papapetropoulos, Spyros
    Liu, Wenlei
    Duvvuri, Sridhar
    Thayer, Kathleen
    Gray, David L.
    [J]. NEURODEGENERATIVE DISEASES, 2018, 18 (5-6) : 262 - 269
  • [27] Receptor signaling and behavioral properties of EFF0311, a longer-acting selective full D1 agonist as a potential treatment for Parkinson's disease
    Murthy, Vishakantha
    Lieu, Christopher A.
    Gowdahalli, Krishnegowda
    Blake, Daniel, Jr.
    Amin, Shantu
    Subramanian, Thyagarajan
    Mailman, Richard B.
    [J]. FASEB JOURNAL, 2010, 24
  • [28] A-86929 - A POTENT AND SELECTIVE DOPAMINE (DA) D1 AGONIST WITH EFFICACY IN RODENT AND PRIMATE MODELS OF PARKINSONS-DISEASE (PD)
    MICHAELIDES, MR
    ASIN, KE
    BIANCHI, B
    BRITTON, DR
    DIDOMENICO, S
    HODGES, L
    HONG, YF
    LIN, CW
    MIKUSA, J
    MILLER, T
    NIKKEL, A
    SMITH, L
    STASHKO, M
    WILLIAMS, M
    JENNER, P
    SHIOSAKI, K
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1995, 209 : 83 - MEDI
  • [29] Phospholipase D1 downregulation by α-synuclein: Implications for neurodegeneration in Parkinson's disease
    Conde, Melisa A.
    Alza, Natalia P.
    Iglesias Gonzalez, Pablo A.
    Scodelaro Bilbao, Paola G.
    Sanchez Campos, Sofia
    Uranga, Romina M.
    Salvador, Gabriela A.
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2018, 1863 (06): : 639 - 650
  • [30] Phase 1 Parkinson's Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolerated
    Sohur, U. Shivraj
    Gray, David L.
    Duvvuri, Sridhar
    Zhang, Yao
    Thayer, Kathleen
    Feng, Gang
    [J]. NEUROLOGY AND THERAPY, 2018, 7 (02) : 307 - 319
12345